NET ASSET VALUE – 31 August 2024

MARKN.

On the 31 August 2024 Flerie AB's Net Asset Value (NAV) was SEK 4,360 million and NAV per share was SEK 55.85.

Allocation of NAVShare of portfolio companyFair value (MSEK)Part of NAV per share (SEK)Share of NAV

     
Product Development    
Prokarium42%4736.0610.9%
Xspray Pharma18%3033.887.0%
Xintela56%2052.634.7%
Empros Pharma79%2042.624.7%
KAHR Medical31%1932.474.4%
Atrogi37%1762.254.0%
Lipum57%1481.903.4%
Microbiotica11%1351.733.1%
Mendus24%1031.322.4%
Geneos Therapeutics12%981.262.3%
Toleranzia58%580.751.3%
EpiEndo Pharmaceuticals9%560.721.3%
Synerkine Pharma43%520.671.2%
AnaCardio19%520.661.2%
Egetis Therapeutics2%420.531.0%
Buzzard Pharmaceuticals14%290.370.7%
Vitara Biomedical5%270.350.6%
Sixera Pharma23%260.330.6%
Alder Therapeutics21%170.220.4%
Amarna Therapeutics60%110.150.3%
Strike Pharma16%90.110.2%
Total
2,41930.9855.5%
     
Commercial Growth    
NorthX Biologics92%1892.424.3%
Symcel31%1692.163.9%
A3P Biomedical8%750.961.7%
Chromafora31%730.931.7%
Provell Pharmaceuticals72%680.871.6%
Nanologica39%420.541.0%
Frontier Biosolutions2%190.240.4%
Bohus Biotech45%170.210.4%
Total
6518.3414.9%
     
Limited Partnerships, total
871.112.0%






Assets related to portfolio companies
3985.109.1%
Other assets and liabilities
80510.3218.5%






NAV
4 36055.85100.0%
     
* indirect shares in Provell Pharmaceuticals
 
   
Datum 2024-09-03, kl 08:00
Källa MFN
Kom igång med ditt sparande på bara några minuter! Hos Avanza handlar du aktier från 0 kr på Stockholmsbörsen och får tillbaka alla fondavgifter (ja, alla!) upp till 50 000 kr i samlat sparande. Kanske är det därför Avanza har Sveriges nöjdaste sparare 15 år i rad.
Investeringar innebär en risk